GenFleet Therapeutics Shanghai Inc. (Ticker: 2595 HK) is a China-based biotechnology company developing innovative medicines for cancer, autoimmune, and inflammatory diseases. Founded in 2017, the company has built a pipeline of eight drug candidates, five of which are in clinical development. Its lead product, Dupert, is approved in China for treating lung cancer, and the company is advancing additional treatments for solid tumors and immune-related conditions. GenFleet plans to list on the Hong Kong Stock Exchange on September 19, 2025, offering 77.6 million primary shares at HKD 20.39 each, raising HKD 1.58 billion (USD 203 million), with an option to sell an additional 15% through a greenshoe. The IPO implies a market capitalization of about USD 904 million. Funds from the offering will be used to support research, clinical trials, and pipeline expansion. The deal is managed by a syndicate including ABCI Capital, BOCOM International, CCB International, CLSA, China Renaissance, and Fosun International.